top of page
TEST image 3.png

Technology

Transforming the treatment of structural heart disease

LEAFLET MODIFICATION

Pioneering a widely accessible interventional solution for aortic leaflet modification

Many patients who are candidates for transcatheter aortic valve replacement (TAVR), for both native aortic stenosis and replacement of a prior bioprosthetic valve, are at risk for coronary obstruction or compromised coronary access.

Aortic Valve.png
Leaflet Modification Solution

Transfemoral access

RF-enabled to control cut and help minimize procedural risks

Low profile

Efficient

Warning: Aortic Solutions is a development stage company and the Myotomy solution is not approved by the FDA.

bottom of page